Categories Earnings Call Transcripts, Preliminary Transcripts
CorMedix Inc (CRMD) Q4 2020 Earnings Call Transcript
CRMD Earnings Call - Final Transcript
CorMedix Inc (NASDAQ: CRMD) Q4 2020 earnings call dated Mar. 30, 2021. Corporate Participants: Dan Ferry — Investor Relations Khoso Baluch — Chief Executive Officer Phoebe Mounts — Executive Vice President and General Counsel Matt David — Executive Vice President and Chief Financial Officer Analysts: Jason Butler — JMP Securities — Analyst Joon Lee — Truist Securities — Analyst Chad Messer — Needham & Company — Analyst Andrew D’Silva — B....
Disclaimer
This transcript is produced by AlphaStreet, Inc. While we strive to produce the best transcripts, it may contain misspellings and other inaccuracies. This transcript is provided as is without express or implied warranties of any kind. As with all our articles, AlphaStreet, Inc. does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company’s SEC filings. Neither the information nor any opinion expressed in this transcript constitutes a solicitation of the purchase or sale of securities or commodities. Any opinion expressed in the transcript does not necessarily reflect the views of AlphaStreet, Inc.
© COPYRIGHT 2021, AlphaStreet, Inc. All rights reserved. Any reproduction, redistribution or retransmission is expressly prohibited.
Most Popular
Bank of New York Mellon Corporation (BK) Earnings: 4Q25 Key Numbers
The Bank of New York Mellon Corporation (NYSE: BK) reported its fourth quarter 2025 earnings results today. Total revenue of $5.2 billion increased 7% on a year-over-year basis. Net income
Delta Air Lines (DAL) Q4 2025 Earnings: Key financials and quarterly highlights
Delta Air Lines (NYSE: DAL) reported its fourth quarter 2025 earnings results today. Total operating revenue increased 3% year-over-year to $16 billion. Net income grew 45% to $1.22 billion, or
Johnson & Johnson heads into Q4 as a more focused healthcare leader
Johnson & Johnson (NYSE: JNJ) is capitalizing on its transition from a broad-based healthcare conglomerate into a market leader in innovative medicine and medical technology. The company continues to expand
